157 related articles for article (PubMed ID: 38254758)
1. Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data.
Gurruchaga Sotés I; Gómez-Mateo MC; Ortega Izquierdo ME; Martínez-Trufero J
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254758
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
3. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Losa R; Fra J; López-Pousa A; Sierra M; Goitia A; Uña E; Nadal R; Del Muro JG; Gión M; Maurel J; Escudero P; Esteban E; Buesa JM
Cancer Chemother Pharmacol; 2007 Feb; 59(2):251-9. PubMed ID: 16736150
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Sharma S; Takyar S; Manson SC; Powell S; Penel N
BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
7. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J
Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
11. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X
Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Dileo P; Morgan JA; Zahrieh D; Desai J; Salesi JM; Harmon DC; Quigley MT; Polson K; Demetri GD; George S
Cancer; 2007 May; 109(9):1863-9. PubMed ID: 17385194
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
19. Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers.
Choi JH; Park H; Park JK; Lee JK; Lee KT; Lee KH
Ther Adv Med Oncol; 2024; 16():17588359231225045. PubMed ID: 38249335
[TBL] [Abstract][Full Text] [Related]
20. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
Nassif EF; Blay JY; Massard C; Dufresne A; Brahmi M; Cassier P; Ray-Coquard I; Pautier P; Leary A; Sunyach MP; Bahleda R; Levy A; Le Pechoux C; Honoré C; Mir O; Le Cesne A
ESMO Open; 2022 Apr; 7(2):100425. PubMed ID: 35255445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
